The University of Maryland School of Medicine plans to cut the ribbon on the university system’s largest academic building ever Wednesday, a $305 million tower on Baltimore Street that officials say will vastly expand the institution’s ability to understand and treat diseases.
The Food and Drug Administration (FDA) has approved a new antiviral influenza treatment.
Johns Hopkins’ Social Innovation Lab is kicking off a new cohort of early-stage social enterprises addressing challenges around education, health and blight, among others.
Thrombocytopenia is a big word that can carry big consequences for those struggling with rare blood disorders, especially among those using heparin to treat and prevent blood clots. But, help is on the way. The National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI) recently awarded VERALOX Therapeutics, a small molecule drug discovery and development company, a $319,133 Small Business Innovation Research grant to develop a novel therapeutic for patients suffering from heparin-induced thrombocytopenia and thrombosis (HIT/HITT).
AstraZeneca, and its global biologics research and development arm MedImmune, today announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company’s oncology portfolio and bringing new medicines to patients more quickly. The extended collaboration will enrich AstraZeneca’s immuno-oncology (IO) portfolio with pre-clinical and clinical potential new medicines.
Developers qualify if they fill buildings with biotech and cyber firms.
The chief executive will stay in his role, and on the board, until his successor is appointed or early next year, whichever comes first.
he man was 66 when he came to the hospital with a serious skin infection. He had a fever and low blood pressure, as well as a headache. His doctors gave him a brain scan just to be safe. They found a very small bulge in one of his cranial arteries, which probably had nothing to do with his headache or the infection.
American Gene Technologies (AGT), a leading gene and cell therapy company in the discovery and development of lentiviral vector based therapeutics, announces that the U.S. Food and Drug Administration (FDA) received orphan-drug designation #DRU-2018-6572 for the treatment of phenylketonuria (PKU) using its proprietary, lentiviral vector based technology. PKU is a debilitating inherited disease affecting 1 in 13,500 children born in the U.S. Mandatory screening identifies affected children who can be supported with a strict synthetic diet that does not cure disease. If successful, AGT’s lentiviral vector approach will provide a permanent cure, improving quality of life for more than 16,000 people living with PKU in the U.S. alone.
PathoVax, a Johns Hopkins–born startup developing a vaccine for human papillomavirus virus (HPV), raised $2.75 million in new funding, cofounder Joshua Wang said.
